Invention Grant
- Patent Title: 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and use thereof in the treatment of cancer
-
Application No.: US16484183Application Date: 2018-02-08
-
Publication No.: US11078191B2Publication Date: 2021-08-03
- Inventor: Sanela Bilic , Juan Alberto Camacho Gomez , John Scott Cameron , Julio Cesar Castro-Palomino Laria , Danny Roland Howard, Jr.
- Applicant: Novartis AG , Palobiofarma S.L.
- Applicant Address: CH Basel; ES Mataro Barcelona
- Assignee: Novartis AG,Palobiofarma S.L.
- Current Assignee: Novartis AG,Palobiofarma S.L.
- Current Assignee Address: CH Basel; ES Mataro Barcelona
- Agent Michelle Han
- International Application: PCT/IB2018/050783 WO 20180208
- International Announcement: WO2018/146612 WO 20180816
- Main IPC: C07D403/14
- IPC: C07D403/14 ; C07K16/28 ; A61K31/506 ; A61P35/00
Abstract:
This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-pyrazol-4-ol, as well as processes for its preparation and its use in the treatment of cancer alone of in combination with one or more immunotherapeutic agents.
Information query
